Diverse roles of FOXO family members in gastric cancer

• Published in: World journal of gastrointestinal oncology 2021-10, Vol.13 (10), p.1367-1382
• Main Authors: Chen, Yu-Han, Li, Chun-Lan, Chen, Wen-Jia, Liu, Jing, Wu, Hua-Tao
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 1948-5204; 1948-5204
• DOI: 10.4251/wjgo.v13.i10.1367

Gastric cancer (GC) is the fifth most diagnosed cancer and the third leading cause of cancer-related death worldwide. Although progress has been made in diagnosis, surgical resection, systemic chemotherapy, and immunotherapy, patients with GC still have a poor prognosis. The overall 5-year survival rate in patients with advanced GC is less than 5%. The FOXO subfamily, of the forkhead box family of transcription factors, consists of four members, FOXO1, FOXO3, FOXO4, and FOXO6. This subfamily plays an important role in many cellular processes, such as cell cycle, cell growth, apoptosis, autophagy, stress resistance, protection from aggregate toxicity, DNA repair, tumor suppression, and metabolism, in both normal tissue and malignant tumors. Various studies support a role for FOXOs as tumor suppressors based on their ability to inhibit angiogenesis and metastasis, and promote apoptosis, yet several other studies have shown that FOXOs might also promote tumor progression in certain circumstances. To elucidate the diverse roles of FOXOs in GC, this article systematically reviews the cellular functions of FOXOs in GC to determine potential therapeutic targets and treatment strategies for patients with GC.